For a patient with a chronic autoimmune condition, a monthly treatment can mean a half-day lost to a clinic chair, tethered to an IV pole. The biologic drugs that manage these diseases are often too thick and viscous to push through a standard syringe, consigning them to slow, intravenous infusions. A San Francisco startup, CoFlo Medical, is betting that a clever redesign of the needle itself could collapse that timeline from hours to seconds, potentially shifting where and how millions of patients receive their care [MIT Sloan, May 2025].
The company’s core invention is an annular-flow injector, a device that surrounds a high-viscosity drug with a thin layer of a lower-viscosity lubricating fluid as both pass through the needle. This sheath dramatically reduces the force required for injection, a critical barrier for the concentrated, high-dose biologics that are becoming the standard for many complex conditions [CoFlo Medical, retrieved 2026]. In laboratory demonstrations, the technology has shown injection-force reductions of more than 200 times for drugs above 1,000 centipoise (cP) in viscosity, a threshold that stymies conventional syringes [Perplexity Sonar Pro Brief, retrieved 2026].
The Fluid Dynamics of Access
The bet is not merely about patient convenience, though that is a powerful motivator. It’s about expanding therapeutic access. As drug developers create more potent, targeted biologics, they often formulate them at higher concentrations to deliver effective doses in smaller volumes. This creates a delivery paradox: the more powerful and concentrated the drug, the harder it is to physically administer. The standard workaround is dilution and a slow IV drip, which anchors treatment to clinical settings with trained staff and specialized equipment.
CoFlo’s proposed alternative is a rapid subcutaneous injection, enabled by its force-reducing technology. The company claims its devices can deliver drugs more than ten times faster than existing methods and are designed for use with small-gauge needles [MIT School of Engineering, June 2025]. If the technology proves out in clinical development, the implications are significant. Therapies for conditions like rheumatoid arthritis, psoriasis, and certain cancers could move from infusion centers to outpatient clinics, specialty pharmacies, or even a patient’s home, reducing systemic cost and burden.
From MIT Lab to Pharma Pipeline
The company’s origins are deeply academic. CoFlo is a spinout from the lab of MIT Professor Kripa K. Varanasi, a mechanical engineer whose research into fluid interfaces forms the scientific foundation. He co-founded the company in 2022 with Simon Rufer, now CEO, and Vishnu Jayaprakash, who serves as Chief Business Officer [Perplexity Sonar Pro Brief, retrieved 2026]. The team’s early validation came from winning the grand prize at the MIT $100K startup competition in 2025, a signal of the technology’s potential impact [Simon Rufer LinkedIn, retrieved 2026].
Commercial traction, however, is measured in pharmaceutical partnerships, not competition trophies. CoFlo reports it is now working with five of the twenty largest global pharmaceutical companies on next-generation therapies, according to a November 2026 funding announcement [DevCuration, November 2026]. This builds on an earlier report from May 2025 that cited work with three pharma companies across six drug programs [MIT Sloan, May 2025]. The progression suggests the startup is moving from initial feasibility studies toward more integrated development partnerships.
| Role | Name | Background |
|---|---|---|
| Co-Founder & CEO | Simon Rufer | SM ’22, MIT [Perplexity Sonar Pro Brief, retrieved 2026] |
| Co-Founder & CBO | Vishnu Jayaprakash | PhD ’21 [Perplexity Sonar Pro Brief, retrieved 2026] |
| Co-Founder & Chairman | Kripa K. Varanasi | Professor of Mechanical Engineering, MIT [Varanasi Research Group, retrieved 2026] |
The $6 Million Path to the Clinic
In November 2026, CoFlo Medical secured a $6 million seed round led by J2 Ventures to advance its hardware and software platform toward clinical and regulatory milestones [Dealroom, November 2026]. The capital is earmarked for scaling device production and navigating the complex pathway to regulatory clearance. The company is actively hiring senior device engineers focused on developing an FDA-ready system, according to job postings [MBC BioLabs, retrieved 2026].
The funding round and partnership pipeline point to a clear, capital-intensive roadmap. The company must now transition from compelling lab data and pharma feasibility studies to producing a robust, manufacturable device that can withstand the scrutiny of human trials and regulatory review. This phase introduces a different set of risks.
- Regulatory complexity. The device will likely require a 510(k) clearance or De Novo classification from the U.S. FDA, a process that demands rigorous human factors testing and clinical data to demonstrate safety and substantial equivalence or novel effectiveness.
- Integration burden. For a drug-device combination product, success depends on smooth integration with a pharmaceutical partner’s drug formulation and clinical development timeline, adding layers of coordination and potential delay.
- Manufacturing scale. Producing a precision medical device at commercial scale, with consistent quality, is a classic hardware challenge that has tripped up many promising biotech tools.
The Patient at the End of the Needle
The ultimate test for CoFlo will be measured in disease states and patient populations. The initial target is likely patients with chronic inflammatory and autoimmune conditions who currently receive monoclonal antibodies or other biologic therapies via prolonged IV infusion. For someone with rheumatoid arthritis, Crohn's disease, or plaque psoriasis, the standard of care today often involves traveling to an infusion center every four to eight weeks, where a nurse administers the drug over one to several hours. This consumes a patient’s day, requires insurance pre-authorization for the facility fee, and ties up clinical resources.
Shifting even a subset of these treatments to a rapid subcutaneous injection could reshape the patient experience, offering faster administration in more flexible settings. The next twelve months for CoFlo will be defined by its ability to lock in a lead pharmaceutical development partner and initiate the formal studies required for regulatory submission. If its annular-flow technology can navigate from the benchtop to the bedside, it won’t just be a faster injection. It could be a fundamental redesign of a therapeutic pathway, turning a clinical procedure into a simple shot.
Sources
- [CoFlo Medical, retrieved 2026] CoFlo Medical: Inject the Uninjectable | https://coflo-medical.com/
- [MIT Sloan, May 2025] CoFlo Medical’s plan for faster, cheaper drug injection wins MIT $100K | https://mitsloan.mit.edu/ideas-made-to-matter/coflo-medicals-plan-faster-cheaper-drug-injection-wins-mit-100k
- [MIT School of Engineering, June 2025] Drug injection device wins MIT $100K Competition | https://engineering.mit.edu/connect/news/drug-injection-device-wins-mit-100k-competition/
- [Dealroom, November 2026] CoFlo Medical raises $6M Seed to rethink the injection needle | https://dealroom.co/news/174777-coflo-medical-raises-6m-seed-to-rethink-the-injection-needle/
- [DevCuration, November 2026] CoFlo Medical Announces $6M Seed for Drug Delivery | https://devcuration.com/articles/coflo-medical-6m-seed-drug-delivery
- [Perplexity Sonar Pro Brief, retrieved 2026] CoFlo Medical company brief
- [Varanasi Research Group, retrieved 2026] People - Varanasi Research Group - MIT | https://varanasi.mit.edu/people/
- [Simon Rufer LinkedIn, retrieved 2026] Simon Rufer profile
- [MBC BioLabs, retrieved 2026] CoFlo Medical job posting | https://mbcbiolabs.com/job/coflo-medical-san-francisco-full-time-senior-principal-device-engineer-drug-delivery-2/